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Purpose. TRPV1 is a multimodal channel mainly expressed in sensory neurons. We aimed to explore the pharmacodynamics of
the TRPV1 agonists, capsaicin, natural capsaicinoids, and piperine in an in vitro bioassay using human PC-3 cells and to examine
desensitization and the effect of the specific antagonist SB366791.Methods. PC-3 cells expressingTRPV1were incubatedwith Fluo-4.
Fluorescence emission changes following exposition to agonists with and without preincubation with antagonists were assessed
and referred to maximal fluorescence following the addition of ionomycin. Concentration-response curves were fitted to the Hill
equation. Results. Capsaicin and piperine had similar pharmacodynamics (𝐸max 204.8 ± 184.3% piperine versus 176.6 ± 35.83%
capsaicin, 𝑃 = 0.8814, Hill coefficient 0.70 ± 0.50 piperine versus 1.59 ± 0.86 capsaicin, 𝑃 = 0.3752). In contrast, capsaicinoids had
lower 𝐸max (40.99 ± 6.14% capsaicinoids versus 176.6 ± 35.83% capsaicin, 𝑃 < 0.001). All the TRPV1 agonists showed significant
desensitization after the second exposition and their effects were strongly inhibited by SB366791. Conclusion. TRPV1 receptor is
successfully stimulated by capsaicin, piperine, and natural capsaicinoids. These agonists present desensitization and their effect
is significantly reduced by a TRPV1-specific antagonist. In addition, PC-3 cell bioassays proved useful in the study of TRPV1
pharmacodynamics.
1. Introduction
The transient receptor potential family V member 1 cation
channel (TRPV1) is a nonselective channel that responds to
noxious stimuli such as low pH, painful heat, and irritants.
Identification of TRPV1 through molecular cloning such as
the capsaicin receptor [1] represented amilestone in the study
of noxious stimuli. Since then, many studies have tried to
determine its druggability and pharmacological characteriza-
tion [2–4].
TRPV1 is mainly expressed in unmyelinated C fibers and
in A𝛿 thinly myelinated fibers of the dorsal root (DRG),
trigeminal ganglion (TG), and visceral afferent fibers and it
plays an important role in temperature and pain perception.
However, TRPV1 expression is not exclusive to neuronal
tissue but can be found in other locations such as urothelial
and epithelial cells [5, 6], which respond first to irritating
and inflammatory stimuli together with afferent nociceptors
[7, 8].
Upregulation of TRPV1 expression has been observed in
various diseases [9] including those associated with visceral
hypersensitivity such as irritable bowel syndrome [10] and
other diseases like chronic cough [11] and neuropathic pain
[12]. Downregulation of TRPV1 has been observed in some
diseases such as periodontitis [13]. Strategies aiming to block
or desensitize TRPV1 have been explored to treat several dis-
eases such as neuropathic pain, spinal detrusor hyperreflexia,
bladder hypersensitivity, and pruritus [3].Hence, TRPV1 ago-
nists and antagonists have become essential pharmacological
tools to address the treatment of these disorders.
Most bioassays aiming to characterize the pharmacody-
namics of these TRPV1 ligands use human cells such as
HEK293 heterologously expressing TRPV1 [14]. However,
this technology is not available for most research groups
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and has some limitations in studies concerning excitable
receptors due to the differences between the original cell and
the engineered one [15].There are also problems derived from
the heterologous expression technique such as insertional
alterations. Recently, Sa´nchez et al. [16] demonstrated the
natural expression of TRPV1 in two human prostate cell
cultures: PC-3 and LNCaP. They did this by means of retro-
transcription polymerase chain reaction (RT-PCR), Western
Blot, and binding studies. Thus, PC-3 was shown to be a
human prostate epithelial cancer cell line that could be used
to examine TRPV family receptors pharmacodynamics in
future studies.
The aim of the present study was to explore the pharma-
codynamics of TRPV1 agonists (capsaicin, natural capsaici-
noids, and piperine) in a bioassay using human PC-3 cells
prior to performing a clinical study.
2. Material and Methods
2.1. Experimental Design. In this bioassay, we compared
the pharmacodynamics of capsaicin, natural capsaicinoids,
and piperine and studied the effect of desensitization after
repeated exposure and the effect of the specific TRPV1
antagonist, SB366791.
2.2. Cell Culture and Calcium Imaging. Human Caucasian
prostate adenocarcinoma PC-3 cells expressing TRPV1
(ECACC Catalogue no. 90112714, Salisbury, UK) were grown
in RPMI 1640 medium supplemented with 10% fetal bovine
serum, 100UI/mL penicillin G, 100 𝜇g/mL streptomycin, and
0.25 𝜇g/mL amphotericin B (all from Invitrogen, Paisley,
UK) at 37∘C and 5% CO
2
. Cells were passed every 3-4
days and only cells from passage 25 or lower were used in
the study. Twenty-four hours before the experiment, cells
were passed to a 35mm plate with a glass cover slip. Before
the assay, cells were incubated with extracellular medium
(140mMNaCl, 4.8mMKCl, 1mM MgCl
2
⋅6H
2
O, 1.8mM
CaCl
2
⋅2H
2
O, 10mM glucose, and 10mMHEPES; pH 7) con-
taining 3.64 𝜇M of Fluo-4 AM (Molecular Probes, Eugene,
OR, USA) at room temperature for 45min. Cover slips were
then mounted in an imaging chamber and continuously per-
fused with the extracellular medium. The cells were imaged
with IX-FLA equipment (Olympus Biosystems, Heidelberg,
Germany) connected to an Olympus IX70 microscope with a
20x lens.The timing of the experiments consisted of 10 s ago-
nist expositions, 5min antagonist incubations, and 10min of
interexposition periods. Ionomycin (10𝜇M) was added at the
end of each experiment as a control of fluorescence. Images
were recorded for 40 s at 2.5Hz, and fluorescence emission
changes weremeasured after each agonist addition at 488 nm.
2.3. Drugs and Reagents. Capsaicin, SB366791 (both from
Tocris, Bristol, UK), piperine, and ionomycin (from Sigma
Aldrich, St Louis, MO, USA) were dissolved in dimethyl
sulfoxide (DMSO) 1mM. Final concentrations were obtained
by dissolution of drugs in extracellularmedium.Capsaicinoid
concentration in capsaicinoid sauce (McIlhenny Co, Avery
Island, LA, USA) was determined using liquid chromatog-
raphy (AOAC 995.03) and was 185.5 𝜇g/g, the final desired
concentration being obtained by dissolution in extracellular
medium.
2.4. Data Analysis. The analysis was performed with the
Cell software (Olympus Biosystems, Heidelberg, Germany).
Fluorescence from individual cells was monitored as a func-
tion of time by drawing a region surrounding the inner
part of the cell membrane, the region of interest (ROI), and
measuring the total fluorescent signal from this region. A
total of 10 ROI were selected from each plate. Maximum
intensity of fluorescence (𝐹max) was measured at the end
of the experiment following the application of the Ca2+
ionophore, ionomycin (1 𝜇M). Background fluorescence was
determined by measuring the fluorescent signal of a ROI
without a cell and was subtracted from the increases in
cell fluorescence (Δ𝐹). These were calculated as the mean
of the peak fluorescence value and the fluorescence value
of 2 frames before and 2 frames after the peak, minus the
basal fluorescence at the onset of the recording (the mean
fluorescence value over the 10 first frames) (Figure 1). All
experimentswere carried out at room temperature (18–20∘C).
2.5. StatisticalMethods. Concentration-response curveswere
fitted to theHill equation. Variables in the equation are shown
as mean ± SEM and contrasted by means of a Student 𝑡-
test for nonpaired data. The nonparametric Mann-Whitney
𝑈 test was used to analyze desensitization and antagonism.
Statistical significance was accepted if 𝑃 values were less
than 0.05. Statistical analysis was performed using GraphPad
Prism 5.01 (San Diego, CA, USA).
3. Results
3.1. Pharmacodynamics of TRPV1 Agonists. Capsaicin, the
reference agonist of TRPV1, and piperine caused a concen-
tration-dependent response in PC-3 cells, achievingmaximal
effect at 10−5 and 10−3M, respectively, with similar 𝐸max
(204.8 ± 184.3% piperine versus 176.6 ± 35.83% capsaicin,𝑃 =
0.8814) andHill coefficient (0.70 ± 0.50 piperine versus 1.59 ±
0.86 capsaicin, 𝑃 = 0.3752) and not significantly different
EC
50
(4.14 ⋅ 10−4Mpiperine versus 1.90 ⋅ 10−6Mcapsaicin,𝑃 =
0.0675). Natural capsaicinoids also caused a concentration-
dependent intracellular calcium increase, with significantly
lower 𝐸max than capsaicin (40.99 ± 6.14% capsaicinoids
versus 176.6± 35.83% capsaicin, 𝑃 < 0.001), and similar EC
50
(4.36 ⋅ 10−6M capsaicinoids versus 1.90 ⋅ 10−6M capsaicin,
𝑃 = 0.1601) and Hill coefficient (1.18 ± 0.45 capsaicinoids
versus 1.59 ± 0.86 capsaicin, 𝑃 = 0.674) (Figure 2).
3.2. Specificity: Desensitization and the Effect of an Antagonist.
Repetitive expositions to capsaicin (10−6M, 10min interexpo-
sition), piperine (10−3Mand 10−4M, 10min interexposition),
or natural capsaicinoids 1.2 ⋅ 10−5M (10min interexposition)
significantly reduced the response of PC-3 cells. The effect of
capsaicin was reduced by 38.31 ± 4.08%, piperine by 67.61 ±
5.31%, and capsaicinoids by 22.30 ± 2.24% after second
exposition (Figure 3). In addition, 5min incubation with
the specific TRPV1 antagonist SB366791 (10−5M), strongly
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Figure 1: Calcium imaging data analysis. The regions of interest (ROIs) of 10 cells per plate (colored ellipsis) are marked to measure changes
in fluorescence and a ROI without cells (dark red rectangle) is also marked to measure the background signal (a). Increases in fluorescence
are plotted as a time function for each cell. The increase of fluorescence (Δ𝐹) is calculated as the difference between the mean of the peak and
2 frames backward and forward (narrow rectangle measurements) and the mean of the measurements of 10 frames before agonist exposition
(wide rectangle of measurements); the background signal (red line) is then subtracted (b).
antagonized the response of capsaicin (10−6M), piperine
(10−3M), and capsaicinoids (1.2 ⋅ 10−5M). Following 5min
incubation with the antagonist and 5min wash before second
exposition, the effect of capsaicin was reduced by 74.66 ±
2.93%; piperine by 100± 0.005%, and capsaicinoids by 91.71±
2.76% (Figure 3).
4. Discussion
The results show that capsaicin and piperine to a greater
degree and natural capsaicinoids to a lesser degree success-
fully stimulate the TRPV1 channel. Repeated exposition of
these agonists decreases the effect on TRPV1, suggesting
desensitization.Moreover, their effect is significantly reduced
by a TRPV1-specific antagonist, showing their action to be
specific to this receptor. PC-3 cells were found to be perfectly
adequate tools to study TRPV1 pharmacodynamics.
Caterina et al. studied the pharmacology of rVR1 when
they first cloned it [1]. Since then, several groups have
evaluated the use of TRPV1 as a therapeutic target to treat
various diseases [3, 4]. In our research, TRPV1 is a promising
target to treat oropharyngeal dysphagia, a major complaint
among the elderly and patients with neurological diseases,
and one characterized by pharyngeal and laryngeal sensory
deficits and delayed and prolonged swallow response [17].
Previous clinical studies showed capsaicin and piperine to be
effective in improving the swallowing response [18, 19] but we
needed more knowledge of the TRPV1 agonists’ pharmaco-
dynamics to design a clinical trial to assess proof of concept
[20]. We used a bioassay to evaluate the pharmacology
of capsaicin, piperine, and natural capsaicinoids on human
TRPV1 constitutively expressed in PC-3 cells.
In our study, capsaicin and piperine had similar 𝐸max
and Hill coefficient values and we did not find significant
differences in their EC
50
values, while comparable assays
found a lower maximum effect for piperine and significant
differences in their EC
50
[21, 22]. We also found that natural
capsaicinoid sauce has lower 𝐸max than capsaicin or piperine.
This could be explained by the fact that capsaicinoid sauce
contains different capsaicinoids, one of which is capsaicin,
found in previous studies to have the greatest pungent effect
among vanilloids [23]. Our results helped us determine the
following optimal concentrations for the clinical trial: 10𝜇M
for capsaicin, 150 𝜇M to 1mM for piperine, and 150𝜇M for
capsaicinoid sauce [20].
Our results also showed that all the agonists tested
undergo desensitization after repeated exposition. Capsaicin
had already been shown to desensitize TRPV1 action [1,
21, 24], and Liu and Simon had shown that piperine also
desensitizes TRPV1 action [21], but in our assay piperine
desensitized TRPV1 action to a greater degree.
Finally, the use of TRPV1-specific antagonist SB-366791
allowed us to verify that the effect of our agonists is specific to
TRPV1. In previous studies, capsazepinewas used as a specific
vanilloid receptor antagonist to assess agonist specificity, but
it has nonselective actions on other receptors and apparent
modality-specific properties. SB-366791, however, is a TRPV1
antagonist with high potency and improved selectivity profile
with respect to other commonly used TRPV1 antagonists
[25]. Another difference between our study and previous ones
is the assay design with PC-3 cells, a system that has been
rarely used in comparison with transfected HEK293 cells.
This study shows that PC-3 cells are a good surrogate to test
TRPV1 pharmacology and more accessible as they do not
require transfection.
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Figure 2: Calcium transients and dose-response curves. The means of measurements for each agonist concentration are plotted as time
functions of the increase in fluorescence related to the signal before exposition (a, c, and e); ionomycin was applied at the end of each
experiment and its maximum effect was used to normalize the effect of the different agonists and concentrations. The slope showing calcium
entrance induced by capsaicin and piperine exposition (capsaicin 830.1 ± 128.1 relative increase of fluorescence per second and piperine 1238 ±
146.8 relative increase of fluorescence per second) (a, c) is sharper than the slope showing calcium entrance induced by natural capsaicinoids
exposition (184.6 ± 17.39 relative increase of fluorescence per second) (e). The normalized effect of each concentration is plotted as a dose-
response curve for each agonist. Each point represents the mean ± SEM of 3 independent experiments (𝑛 = 10) (b, d, and f).
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Figure 3: Desensitization and antagonist effect. Capsaicin, capsaicinoids, and piperine normalized first exposition effect (black box) is
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box). Data is expressed as mean ± SEM. ∗
𝑃
< 0.05, ∗∗∗
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< 0.001.
5. Conclusion
In summary, we have examined the pharmacological param-
eters of TRPV1 agonists and analysed desensitization and
the effect of the antagonist SB366791 using an alternative
methodology more easily accessible to most research groups.
We reached our goal of testing capsaicin, piperine, and nat-
ural capsaicinoid pharmacodynamics for subsequent clinical
assays.
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